Company Overview and News

8% Dividend Yield And 19% Upside With MedEquities Realty Trust

2018-04-21 seekingalpha
At a price/FFO of 8.45x, MRT is trading at the second lowest multiple in the entire healthcare sector.
Upvote Downvote

The RIC-Team: April 2018 Review

2018-04-20 seekingalpha
Nonetheless, the R-Team is outperforming its respective benchmarks so at least from that perspective something is working.
Upvote Downvote

IBM Stock Price - International Business Machines Corp. Stock Quote (U.S.: NYSE) - MarketWatch

2018-04-17 marketwatch
International Business Machines Corp. rode the success of old technology to big gains at the end of last year, but investors will be looking for success from newer businesses in order to believe in Big Blue’s future.
Upvote Downvote

Consider This 10.5%-Yielding Health Care REIT For Your Income Portfolio

2018-04-15 seekingalpha
Sabra Health Care REIT is a promising health care REIT for income investors with a high risk tolerance.
Upvote Downvote

If I Had To Build An Income Portfolio Today - Update 28

2018-04-09 seekingalpha
This article is Update 28 to my original article entitled "If I Had to Build An Income Portfolio Today."
Upvote Downvote

Sabra HealthCare (SBRA) Presents At Jefferies 2018 Healthcare REIT Summit - Slideshow

2018-04-04 seekingalpha
The following slide deck was published by Sabra Healthcare REIT, Inc. in conjunction with this event.
Upvote Downvote

Top Analyst Upgrades and Downgrades: AMD, Broadcom, DR Horton, Dollar Tree, Jack in the Box, Zebra Technologies and More

2018-03-26 247wallst
The futures were up big Monday morning as fears of an all-out trade war start to subside. There are reports that the Trump administration has sent a letter to Chinese economic overseer Liu He setting out specific requests to help cut China’s massive trade surplus with the United States. They are asking for a tariff cut on U.S. automobiles, more Chinese purchases of U.S. semiconductors and more access to China’s financial sector by American companies.
Upvote Downvote

Sabra Health Care REIT, Inc. to Participate in the Jefferies 2018 Healthcare REIT Summit

2018-03-20 globenewswire
IRVINE, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. (Nasdaq:SBRA) (Nasdaq:SBRAP) announced today that Rick Matros, the company’s Chairman and Chief Executive Officer, Harold Andrews, the company’s Chief Financial Officer, and Talya Nevo-Hacohen, the company’s Chief Investment Officer, will be participating in the Jefferies 2018 Healthcare REIT Summit being held on April 3, 2018 in New York, NY.
Upvote Downvote

Top Analyst Upgrades and Downgrades: Abercrombie, Altria, Century Aluminum, DSW, Ford, Quest Diagnostics, Sunoco and More

2018-03-14 247wallst
Stocks have been mixed all week, but Wednesday’s indications were for the major indices to open up about 0.3%. The bull market is now over nine years old, and investors are trying to weigh the recent volatility to decide how they want to be positioned for the year ahead and beyond. One trend that has kept working is for investors to buy all the big pullbacks.
Upvote Downvote

ETF Month #1: SuperDividend ETF Not So Super

2018-03-08 seekingalpha
I've recently received some member feedback saying that they'd like more ETF analysis. I actually do agree with that assessment, as I've spent significantly more of my time researching CEFs compared to ETFs over the last year, leading to the introduction of features such as the "Weekly CEF Roundup" and the "Chemist's Quality CEF Report" and "Chemist's High-High-Low CEF Report".
Upvote Downvote

If I Had To Build An Income Portfolio Today - Update 27

2018-03-05 seekingalpha
This article is Update 27 to my original article entitled "If I Had to Build An Income Portfolio Today."
Upvote Downvote

Stocks To Watch: Investors Recharge After Soothing Fedspeak

2018-02-24 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
Upvote Downvote

Sabra Healthcare REIT's (SBRA) CEO Rick Matros on Q4 2017 Results - Earnings Call Transcript

2018-02-23 seekingalpha
Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) Q4 2017 Earnings Conference Call February 22, 2018 1:00 PM ET
Upvote Downvote

Sabra Healthcare REIT price target cut to $21 from $22 at Stifel

2018-02-22 marketwatch
Cutter & CO Brokerage, Inc. Buys Bank of America Corporation, Wells Fargo, CRH PLC, Sells Boeing Co, Middlesex Water Co, Lockheed Martin Corp
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 78573L106